In the mammary gland, SERMs demonstrate antiestrogenic activity, but their effects on the estrogen receptors found in the uterus are agonistic, i.e., they stimulate the endometrium to grow, which is a well-documented risk factor for endometrial cancer [2]. This evidence concerns the gene ESR1 and endometrial cancer.